Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients

Malignant pleural mesothelioma (MPM) is a rare and extremely aggressive tumor responsible for over 27,000 deaths per year worldwide ([1,2]). First-line therapeutic approaches include surgery, radiations, and chemotherapy ([2,3]). Regrettably, MPMs are refractory to standard treatments, as demonstrated by the short median overall survival rate (9.5 months) ([3]). A new possible treatment opportunity for MPM patients stems from the introduction of a new class of immunotherapeutic drugs, known as immune checkpoint inhibitors (ICI), that has changed the prognosis of several solid tumors ([2,4]).

Source: Lung Cancer - October 1, 2020 Category: Cancer & Oncology Authors: Nicola Fusco, Valentina Vaira, Ilaria Righi, Elham Sajjadi, Konstantinos Venetis, Gianluca Lopez, Margherita Cattaneo, Massimo Castellani, Lorenzo Rosso, Mario Nosotti, Mario Clerici, Stefano Ferrero Source Type: research